Targeting cancer stem cells as the most aggressive and tumor-initiating cells
Translational Oncology · 2026-03 · 65 · 102669
DOI: 10.1016/j.tranon.2026.102669 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-03. Verfasst von Maryam Sadri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cancer stem cells (CSCs) are a small subpopulation of tumor cells characterized by their self-renewal capacity and the ability to differentiate into different cell types. These partially differentiated cells exhibit properties of both stem cells and cancer cells. CSCs drive tumor initiation and progression by generating additional stem cells through self-renewal and differentiation into heterogeneous populations of tumor cell. They are among the most aggressive tumor cells that contribute to the development of key features of malignancy such as increased proliferation, metastasis, tumor growth, multidrug resistance (MDR), and resistance to radiotherapy and chemotherapy. CSCs are also associated with relapse and minimal residual disease, highlighting their critical role in cancer persistence. Therefore, targeting CSCs is essential to achieve complete tumor eradication. Available evidence suggests that combination therapies that integrate immunotherapy with cytotoxic therapies to concurrently eliminate CSCs and non-CSCs offer a promising approach to completely eradicate cancer. This review summarizes the current strategies employed to target CSCs and improve cancer treatment outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, Iran University of Medical Sciences, Tehran, Iran.
- Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
- Department of Microbiology and immunology, School of Medicine, Shehrekord Universiy of Medical Sciences, Shahrekord, Iran.
- Molecular Allergy Research Laboratory, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia; Centre for Food and Allergy Research, Murdoch children's Research Inst…
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo 90127, Italy.
- Immunology Research Center, Institute of immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. Electronic address: faraji.fat@iums.ac.ir.
Zitieren
APA
Sadri, M., Shafaghat, Z., Roozbehani, M., Dorfaki, M., Kheiri, F., Heidari, S., Mahmoudi, A., & Faraji, F. (2026). Targeting cancer stem cells as the most aggressive and tumor-initiating cells. Translational Oncology, 65, 102669. https://doi.org/10.1016/j.tranon.2026.102669
Vancouver
Sadri M, Shafaghat Z, Roozbehani M, Dorfaki M, Kheiri F, Heidari S, et al. Targeting cancer stem cells as the most aggressive and tumor-initiating cells. Translational Oncology. 2026;65:102669. doi:10.1016/j.tranon.2026.102669
BibTeX
@article{Sadri2026,
author = {Sadri, Maryam and Shafaghat, Zahra and Roozbehani, Mona and Dorfaki, Maryam and Kheiri, Fatemeh and Heidari, Sahel and Mahmoudi, Ali and Faraji, Fatemeh},
title = {Targeting cancer stem cells as the most aggressive and tumor-initiating cells},
journal = {Translational Oncology},
year = {2026},
volume = {65},
pages = {102669},
doi = {10.1016/j.tranon.2026.102669}
}
EUVIMED